PE20130814A1 - Sales de benzimidazolil piridil eteres y formulaciones que las contienen - Google Patents

Sales de benzimidazolil piridil eteres y formulaciones que las contienen

Info

Publication number
PE20130814A1
PE20130814A1 PE2013000257A PE2013000257A PE20130814A1 PE 20130814 A1 PE20130814 A1 PE 20130814A1 PE 2013000257 A PE2013000257 A PE 2013000257A PE 2013000257 A PE2013000257 A PE 2013000257A PE 20130814 A1 PE20130814 A1 PE 20130814A1
Authority
PE
Peru
Prior art keywords
acid
crossed
weight
formulations containing
cross
Prior art date
Application number
PE2013000257A
Other languages
English (en)
Inventor
Rampurna Gullapalli
Ahmad Hashash
Piotr H Karpinski
Kangwen L Lin
Eric M Loeser
Augustus O Okhamafe
Paul Allen Sutton
Eduardo Sy
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20130814A1 publication Critical patent/PE20130814A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Abstract

SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE a) UNA SAL ACIDA {1-METIL-5-[2-(5-TRIFLUOROMETIL-1H-IMIDAZOL-2-IL)-PIRIDIN-4-ILOXI]-1H-BENZOIMIDAZOL-2-IL}-(4-TRIFLUOROMETIL-FENIL)AMINA SELECCIONADO DEL GRUPO ACIDO ASCORBICO, ACIDO MALICO, ACIDO OXALICO, ACIDO LACTICO ENTRE OTROS, EN UNA CANTIDAD DE 0,01%-80% EN PESO; b)AGENTE TENSIOACTIVO SELECCIONADO DE ESTEARATO DE POLIOXIL 40, SUCCINATO DE d-ALFA-TOCOFERIL POLIETILENGLICOL 1000 Y POLOXAMERO 188, EN UNA CANTIDAD DE 0,01%-60% EN PESO; c) VEHICULO SELLECIONADO DEL GRUPO DE POVIDONA ENTRECRUZADA, DEXTRANO ENTRECRUZADO, HIDROXIPROPILMETILCELULOSA, ENTRE OTROS; d) ADEMAS COMPRENDE ANTIOXIDANTE, AGENTE COLORANTE, AGENTE SABORIZANTE, CONSERVANTE Y ENDULZANTE. REFERIDA ADEMAS A UN PROCESO FARMACEUTICA. DICHOS COMPUESTOS SON UTILES PARA EL TRATAMIENTO DE CANCER.
PE2013000257A 2006-08-30 2007-08-29 Sales de benzimidazolil piridil eteres y formulaciones que las contienen PE20130814A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84117706P 2006-08-30 2006-08-30
US95446607P 2007-08-07 2007-08-07

Publications (1)

Publication Number Publication Date
PE20130814A1 true PE20130814A1 (es) 2013-08-08

Family

ID=39027583

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2007001169A PE20080766A1 (es) 2006-08-30 2007-08-29 Sales de benzimidazolil piridil eteres y formulaciones que las contienen
PE2013000257A PE20130814A1 (es) 2006-08-30 2007-08-29 Sales de benzimidazolil piridil eteres y formulaciones que las contienen

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PE2007001169A PE20080766A1 (es) 2006-08-30 2007-08-29 Sales de benzimidazolil piridil eteres y formulaciones que las contienen

Country Status (34)

Country Link
US (2) US8202998B2 (es)
EP (1) EP2059518B1 (es)
JP (1) JP5279712B2 (es)
KR (1) KR20090043542A (es)
CN (1) CN101516870B (es)
AT (1) ATE504584T1 (es)
AU (1) AU2007290388B2 (es)
BR (1) BRPI0716243A2 (es)
CA (1) CA2660376C (es)
CL (1) CL2007002533A1 (es)
CO (1) CO6150180A2 (es)
CY (1) CY1112187T1 (es)
DE (1) DE602007013774D1 (es)
DK (1) DK2059518T3 (es)
ES (1) ES2360968T3 (es)
GT (1) GT200900045A (es)
HK (1) HK1131613A1 (es)
HR (1) HRP20110311T1 (es)
IL (1) IL196811A (es)
JO (1) JO2702B1 (es)
MA (1) MA30711B1 (es)
MX (1) MX2009002279A (es)
MY (1) MY161829A (es)
NO (1) NO20091236L (es)
NZ (1) NZ574620A (es)
PE (2) PE20080766A1 (es)
PL (1) PL2059518T3 (es)
PT (1) PT2059518E (es)
RU (1) RU2457206C2 (es)
SI (1) SI2059518T1 (es)
TN (1) TN2009000068A1 (es)
TW (1) TW200819438A (es)
WO (1) WO2008027523A2 (es)
ZA (1) ZA200900664B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20080766A1 (es) * 2006-08-30 2008-06-15 Novartis Ag Sales de benzimidazolil piridil eteres y formulaciones que las contienen
CN101679372A (zh) * 2007-03-02 2010-03-24 诺瓦提斯公司 Raf激酶抑制剂的固体形式
EP2288354A1 (en) * 2008-06-13 2011-03-02 Novartis AG Substituted benzimidazoles for neurofibromatosis
US20110281917A1 (en) * 2009-01-29 2011-11-17 Darrin Stuart Substituted Benzimidazoles for the Treatment of Astrocytomas
WO2011044072A1 (en) 2009-10-05 2011-04-14 Novartis Ag Combination of raf-265 and an activator of ampk for use in the treatment of a proliferative disease
US20130245061A1 (en) * 2010-12-03 2013-09-19 Novartis Ag Pharmaceutical compositions
AU2020395495B2 (en) * 2019-12-02 2024-05-09 Astrazeneca Ab Solid pharmaceutical formulations of 6-(2-chloro-6-methylpyridin-4-yl)-5-(-4-fluorophenyl)-1,2,4-triazin-3-amine
WO2022083741A1 (zh) * 2020-10-23 2022-04-28 上海辉启生物医药科技有限公司 吡唑并吡啶类化合物或其盐及其制备方法和用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1499311T1 (sl) * 2002-03-29 2010-03-31 Novartis Vaccines & Diagnostic Substituirani benzazoli in njihova uporaba kot inhibitorji Raf kinaze
US8299108B2 (en) * 2002-03-29 2012-10-30 Novartis Ag Substituted benzazoles and methods of their use as inhibitors of raf kinase
US20060189619A1 (en) 2005-02-24 2006-08-24 Wyeth 3-({4-[2-(4-Tert-butylphenyl)-1h-benzimidazol-4-yl]piperazin-1-yl}methyl)pyrido[2,3-b]]pyrazi ne compounds
PE20070335A1 (es) * 2005-08-30 2007-04-21 Novartis Ag Benzimidazoles sustituidos y metodos para su preparacion
US7731795B2 (en) 2005-12-02 2010-06-08 Clemson University Rhombohedral fluoroberyllium borate crystals and hydrothermal growth thereof for use in laser and non-linear optical applications and devices
ATE459338T1 (de) * 2006-07-21 2010-03-15 Novartis Ag Formulierungen für benzimidazolylpyridylether
PE20080766A1 (es) * 2006-08-30 2008-06-15 Novartis Ag Sales de benzimidazolil piridil eteres y formulaciones que las contienen

Also Published As

Publication number Publication date
CL2007002533A1 (es) 2008-02-08
RU2457206C2 (ru) 2012-07-27
US8202998B2 (en) 2012-06-19
WO2008027523A3 (en) 2008-04-10
CN101516870B (zh) 2013-09-11
CY1112187T1 (el) 2015-12-09
DK2059518T3 (da) 2011-05-16
HK1131613A1 (en) 2010-01-29
WO2008027523A2 (en) 2008-03-06
NZ574620A (en) 2011-05-27
JP2010502622A (ja) 2010-01-28
ZA200900664B (en) 2009-12-30
MX2009002279A (es) 2009-03-20
EP2059518A2 (en) 2009-05-20
JP5279712B2 (ja) 2013-09-04
US20120308651A1 (en) 2012-12-06
IL196811A (en) 2013-03-24
US20100168060A1 (en) 2010-07-01
TN2009000068A1 (en) 2010-08-19
CO6150180A2 (es) 2010-04-20
US8501785B2 (en) 2013-08-06
HRP20110311T1 (hr) 2011-08-31
MY161829A (en) 2017-05-15
BRPI0716243A2 (pt) 2013-09-03
TW200819438A (en) 2008-05-01
MA30711B1 (fr) 2009-09-01
AU2007290388B2 (en) 2011-07-14
PL2059518T3 (pl) 2011-09-30
IL196811A0 (en) 2009-11-18
PT2059518E (pt) 2011-07-11
SI2059518T1 (sl) 2011-06-30
RU2009111384A (ru) 2010-10-10
PE20080766A1 (es) 2008-06-15
CN101516870A (zh) 2009-08-26
JO2702B1 (en) 2013-03-03
KR20090043542A (ko) 2009-05-06
ATE504584T1 (de) 2011-04-15
AU2007290388A1 (en) 2008-03-06
CA2660376A1 (en) 2008-03-06
EP2059518B1 (en) 2011-04-06
NO20091236L (no) 2009-03-27
DE602007013774D1 (de) 2011-05-19
CA2660376C (en) 2014-04-15
ES2360968T3 (es) 2011-06-10
GT200900045A (es) 2010-06-14

Similar Documents

Publication Publication Date Title
PE20130814A1 (es) Sales de benzimidazolil piridil eteres y formulaciones que las contienen
ES2540853T3 (es) Sales de dicetopiperazina para la administración de fármacos
JP5372523B2 (ja) 真菌症治療用ゲル組成物
ES2508290T3 (es) Composición farmacéutica para la administracón de compuestos de inhibición del receptor de tirosina cinasa (RTKI) al ojo
CY1121782T1 (el) Διαδικασια για ξηρανση της bibw2992, tων αλατων αυτης και στερεων φαρμακευτικων σκευασματων που περιλαμβανουν αυτο το δραστικο συστατικο
RU2017127135A (ru) Терапевтическое средство против рака желчных протоков
MX2010010647A (es) Proceso para preparar formulaciones de dabigatran para administracion oral.
PE20191755A1 (es) Derivados de pirazol como inhibidores de malt 1
JPWO2007102242A1 (ja) 外用の医薬組成物
EA201070588A1 (ru) Производные 1,2,3-триазола для применения в качестве ингибиторов стеароил-соа десатуразы
EA201070167A1 (ru) Замещенные производные индазола, активные как ингибиторы киназы
SMT201300096B (it) Inibitori di prolil idrossilasi
UY29562A1 (es) Compuestos heterocíclicos de amino benzoilo, composiciones farmacéuticas que los contienen, procedimientos de preparación y aplicaciones
MX2009004475A (es) Composiciones que comprenden agentes acido labiles que inhiben la bomba de protones, por lo menos otro agente farmaceuticamente activo y metodos de uso de las misma.
JPWO2007102241A1 (ja) 外用の医薬組成物
CO6220902A2 (es) Formulacion en polvo del valganciclovir
EA201071094A1 (ru) Тризамещенные 1,2,4-триазолы в качестве модуляторов никотиновых ацетилхолиновых рецепторов
CO2019004190A2 (es) Formulaciones liposomales para uso en el tratamiento del cáncer
CO6361855A2 (es) Derivados de 7-hidroxi-benzoimidazol-4-il-,etanona e inhibidores de cinasa que enlaza pdz que contienen los mismos
EA201001196A1 (ru) Соединения 4-пиридинона и их применение для лечения рака
CU24330B1 (es) Derivados del ácido 4-((1,1) bifenil-4-il)-3-(3-fosfonopropanamido) butanoico, activos como inhibidores de nep (endopeptidasa neutral)
CL2008002316A1 (es) Compuestos heterociclicos nitrogenados que contienen fenilendiamina sustituida, inhibidores de la interaccion entre mdm2 y p53; procedimiento de preparacion; composicion farmaceutica; combinacion farmaceutica; y uso en el tratamiento del cancer.
IN2014DN08870A (es)
AR119614A1 (es) Formas en estado sólido de (s)-2-(((s)-6,8-diflúor-1,2,3,4-tetrahidronaftalen-2-il)amino)-n-(1-(2-metil-1-(neopentilamino)propan-2-il)-1h-imidazol-4-il)pentanamida y usos de la misma
CO2019004004A2 (es) Composición farmacéutica y método para el tratamiento de la enfermedad del hígado graso no alcohólico

Legal Events

Date Code Title Description
FA Abandonment or withdrawal